Europe Biologics CDMO Market: Focus on Cell Type, Molecule Type, and Country - Analysis and Forecast, 2023-2032
Report Highlights
The Europe Biologics CDMO Market Expected to Reach $21.61 Billion by 2032
Introduction to Europe Biologics CDMO Market
The Europe biologics CDMO market is projected to reach $21.61 billion by 2032 from $6.48 billion in 2023, growing at a CAGR of 14.32% during the forecast period 2023-2032. The market's trajectory indicates a transformative impact on pharmaceutical care. Companies that skillfully navigate regulatory complexities and adopt technological innovations are well-positioned for significant success.
Market Introduction
The Europe Biologics CDMO market is experiencing robust growth, driven by increasing demand for biologic therapies, such as monoclonal antibodies, vaccines, and cell and gene therapies. The rise in chronic diseases, advancements in biology, and the growing trend of outsourcing drug development and manufacturing processes are key factors propelling the market. European CDMOs are investing in state-of-the-art facilities and cutting-edge technologies to enhance production capabilities and meet stringent regulatory standards. Strategic collaborations and partnerships are also on the rise, enabling CDMOs to offer comprehensive services from early development to commercial manufacturing. With strong government support and a well-established biopharmaceutical sector, the Europe Biologics CDMO market is poised for sustained expansion and innovation.
Market Segmentation:
Segmentation 1: by Cell Type
- Mammalian
- Microbial and Others
Segmentation 2: by Molecule Type
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Hormones
- Others
Segmentation 3: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
Report Synopsis
| Report Metrics | Details |
| Base year considered | 2023 |
| Forecast period considered | 2023-2032 |
| Base year market size | $6.48 Billion in 2023 |
| Market size forecast | $21.61 Billion by 2032 |
| Growth rate | 14.32% |
| Units considered | $ Billion |
| Segments covered | By Cell Type, By Molecule Type, By Country |
| Industry covered | BIS Healthcare |
| Regions covered | Europe |
| Countries covered | Germany, U.K., France, Italy, Spain, Rest-of-Europe |
| Companies studied |
|
How can this report add value to an organization?
Workflow/Innovation Strategy: The Europe biologics CDMO market (by molecule type) has been segmented into different types of molecules used in developing biologics. Moreover, the study provides the reader with a detailed understanding of the different cell types and indications as well.
Growth/Marketing Strategy: The market growth and marketing strategy of biologics CDMO market revolves around a combination of technical excellence, strategic collaborations, and market positioning. CDMOs leverage their specialized expertise in bioprocessing and manufacturing to offer comprehensive solutions to biopharmaceutical companies.
Competitive Strategy: Key players in the Europe biologics CDMO market have been analyzed and profiled in the study, including CDMOs involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
- Boehringer Ingelheim Group
- Lonza Group
- NOVARTIS AG
This report will be delivered in 1-5 working days.
BIS Research is a global B2B market intelligence and advisory firm focusing on those emerging technological trends which are likely to disrupt the dynamics of the market.
With over 150 market research reports published annually, BIS Research focuses on high technology verticals such as 3D Printing, Advanced Materials and Chemicals, Aerospace and Defense, Automotive, Healthcare, Electronics and Semiconductors, Robotics and UAV, and other emerging technologies.
Our in-depth market intelligence reports focus on the market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.
Similar Reports from BIS Research
Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033
Global Biologics CDMO Market Set to Surge, Riding the Wave of Innovation and Demand
Biologics CDMO Industry Overview
The global biologics CDMO market was valued at $XX billion in 2022 and is anticipated to reach $XX billion by 2033, witnessing a CAGR of XX% during the forecast period 2023-2033.
Introduction to Biologics CDMO Market
The global biologics CDMO market plays ...